Synovus Financial Corp Takes Position in Repligen Co. (NASDAQ:RGEN)

Synovus Financial Corp purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,538 shares of the biotechnology company's stock, valued at approximately $941,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Groupama Asset Managment increased its position in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Repligen in the fourth quarter worth about $52,492,000. Allspring Global Investments Holdings LLC increased its holdings in Repligen by 79.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after buying an additional 203,011 shares during the last quarter. Alliancebernstein L.P. raised its stake in Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after buying an additional 191,439 shares in the last quarter. Finally, Norges Bank bought a new position in Repligen during the 4th quarter worth approximately $24,034,000. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. TD Cowen began coverage on shares of Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a report on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Repligen has an average rating of "Hold" and a consensus target price of $176.82.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded up $5.46 on Tuesday, hitting $137.10. The company's stock had a trading volume of 272,362 shares, compared to its average volume of 706,633. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock's 50-day moving average is $140.09 and its two-hundred day moving average is $145.74. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $7.70 billion, a price-to-earnings ratio of -270.00, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. On average, equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.